| Document |
Document Title |
|
JP3054780B2 |
The use of a progesterone receptor antagonist for the preparation of a pharmaceutical composition for preventing an oocyte from becoming fertilized without preventing ovulation or interfering with the regularity of the ovarian menstrual ...
|
|
JP2000154380A |
To obtain a new spirooxazine derivative having an optical activity, permanently, and useful as an optically functional medium suitable for a recording layer material of an optical recording medium, a forgery-preventing material, an optic...
|
|
JP2000506907A |
Nucleosides and oligonucleosides functionalized to include carbamate functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophili...
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
|
JP3048637B2 |
PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as...
|
|
JP2000143691A |
To obtain the subject new compound enabling immunoassay in high specificity and sensitivity through efficiently competing with a cortisol-like steroid with aiming at binding to an anti-cortisol antibody and exhibiting low cross reactivit...
|
|
JP2000135435A |
To separate estrogen compounds and estrogenic substances by reverse phase high-performance liquid chromatography by introducing a template structure to the estrogen compounds and estrogenic substances into polymer particles. Estrogen com...
|
|
JP3036141B2 |
PURPOSE: To provide the title novel compound having high nonlinear optical performance for wavelength transformation, etc., thus useful for nonlinear optical materials and nonlinear optical elements. CONSTITUTION: The objective compound ...
|
|
JP3034098B2 |
|
|
JP3034093B2 |
PURPOSE: To obtain a catecholestrogen glycoside having improved water solubility and durability of action while maintaining inhibitory action on peroxide lipid. CONSTITUTION: A catecholestrogen glycoside of formula I (R1 is hydroxyl, glu...
|
|
JP2000088834A |
To realize a liquid chromatography(LC) trace amount analysis of a phenol compound, particularly estrogen by previously pentafluorobenzoylating a phenolic hydroxyl group of the phenol compound. A phenol compound is a compound having a hyd...
|
|
JP3026997B2 |
New products (I): in which R1 denotes an aliphatic hydrocarbon radical (C1-8), Ra and Rb denote a hydrogen or an alkyl (C1-4), R2 denotes a hydrogen or an optionally substituted alkyl (C1-12), n denotes one of the values from 1 to 6, Z d...
|
|
JP3020880B2 |
To obtain a hormonal contraceptive pill, based on natural estrogen and capable of realizing the safety of contraception in the progress of the period in the case of a lower estrogen dose and a lower gestagen dose than those of a conventi...
|
|
JP3020727B2 |
PURPOSE: To provide the hair-raising agent excellent in the effects on hair growth, hair raising, alopecia prevention, dander prevention, etc. The compounding ratio of the extract of Aconiti Tuber to estradiol, etc., is suitably selected...
|
|
JP3014784B2 |
A method of relieving stress in fish and increasing resistance to pathogenic agents comprising orally administering to the fish an amount of a compound of the formula I wherein R is alkyl of 1 to 4 carbon atoms and X is acyl of an organi...
|
|
JP3009169B2 |
The invention relates to the compounds (I): in which A and B are either where R2 and R'2 are H or alkyl (C1-4), or where R3 is H or alkyl (C1-4) or acyl, and - either R17 and R'17 together form a ketone, - or R17 is hydroxyl or acyloxy a...
|
|
JP2000026284A |
To administer estrogen at a high rate without adding a permeation promoting agent by integrating estrogen in a matrix containing a pressure- sensitive tacky adhesive copolymer such as vinyl acetate-acrylate copolymer and delivering the e...
|
|
JP3002117B2 |
Combined prepn. for contraception and hormone replacement containing 3 stages with a total of 28 daily dose units (DDU) comprises: (1) a first stage of 3 or 4 DDU, each contg. at least one biogenic oestrogen (I); (2) a second stage of 20...
|
|
JP2999258B2 |
PCT No. PCT/EP91/01018 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18918 PCT Pub. Date Dec. 12, 1991.A process for the production of 10 beta -H-11 beta -(substituted phenyl) steroid...
|
|
JP3000039B2 |
PCT No. PCT/DE91/00562 Sec. 371 Date Jun. 1, 1993 Sec. 102(e) Date Jun. 1, 1993 PCT Filed Jul. 5, 1991 PCT Pub. No. WO92/00991 PCT Pub. Date Jan. 23, 1992.The unsaturated 17 alpha -cyanomethyl-17 beta -hydroxy steroids of the formula I, ...
|
|
JP2999539B2 |
|
|
JP2996723B2 |
New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic g...
|
|
JP2000001415A |
To obtain the subject composition for a topical use, capable of treating wrinkles and fine wrinkles, effectively stiffening skin tissue and subcutaneous tissue and further recovering skin brightness by including a dehydroepiandrosterone ...
|
|
JP2989935B2 |
This invention relates to a process for the preparation of 10-(2-propynyl)-estr-4-ene-3,17-dione, whereby this compound is synthesized utilizing ketals prepared from the addition of 2,2-dimethyl-1,3-propanediol to the starting compound, ...
|
|
JPH11514327A |
The present invention relates to the use of an estrogen compound for protecting a population of nerve cells from death. The compound can be used in the treatment of a subject affected by a neurodegenerative disorder, in order to prevent ...
|
|
JP2980389B2 |
Products of formula (I): in which =X denotes =O or R = H or acyl and the broken lines show the optional presence of one or two additional double bonds, process for their preparation and intermediates of this process, their application as...
|
|
JP2974969B2 |
To obtain a medicinal matrix structure which can administer an effective does of the medicine in no need of skin penetration accelerator. The medicine is dispersed in a matrix containing a pressure- sensitively adhering acrylate copolyme...
|
|
JP2973031B2 |
A method for controlling weight gain or promoting weight loss which includes the step of treating a subject with an effective weight gain controlling or weight loss promoting amount of a substituted (Delta)5-Androstene which is biologica...
|
|
JP2965262B2 |
|
|
JP2961187B2 |
The invention relates to the products of the formula (I): …… in which:… R = alkyl, alkenyl, alkynyl or CN,… R1 = C1-6-alkyl which is unsubstituted or substituted by one or more radicals chosen from among C1-4-alkoxy or alkylthio,...
|
|
JP2959839B2 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
JP2959785B2 |
Disclosed are novel classes of anti-androgens including dihydrophenanthrene derivatives, their method of synthesis and their use in treating disorders associated with excessive androgenic activities.
|
|
JP2959838B2 |
A method of treatment of breast and endometrial cancer in susceptible warm-blooded animals may include inhibition of ovarian hormonal secretion by surgical (ovariectomy) or chemical (use of an LHRH agonist, e.g. [D-Trp6, des-Gly-NH210]LH...
|
|
JP2956776B2 |
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I (I) wherein Z is an oxygen atom or N-OH; R2 is alpha- or beta-position methyl or ethyl; R1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, a...
|
|
JP2954248B2 |
A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C21H28O5 and with a ...
|
|
JP2947938B2 |
|
|
JP2947933B2 |
PCT No. PCT/SE92/00056 Sec. 371 Date Aug. 24, 1993 Sec. 102(e) Date Aug. 24, 1993 PCT Filed Jan. 29, 1992 PCT Pub. No. WO92/13873 PCT Pub. Date Aug. 20, 1992Compounds of the general formula (I), (I) in which formula the 1,2-position is s...
|
|
JPH11241089A |
To provide a composition which generates an in vivo vomeronasal organ negative receptor binding potential in a human subject by making the composition contain a human pheromone containing one or more 16-androstene steroids and one or mor...
|
|
JPH11228593A |
To provide a method for readily purifying tall oil sterol in high purity at high recovery rate from tall oil neutral component. A tall oil neutral component is brought into contact with at least one kind of solvent selected from methanol...
|
|
JPH11509222A |
(57) [Summary] An ester of 13-ethyl-17β-hydroxy-11-methylene-18,19-dinor-17α-pregun-4
-ene-20-in-3-one having 1 to 20 carbon atoms in the ester group is optional. Describes agents for transdermal administration, which are characterized...
|
|
JP2933713B2 |
PCT No. PCT/DE90/00690 Sec. 371 Date Jun. 22, 1991 Sec. 102(e) Date Jun. 22, 1991 PCT Filed Sep. 6, 1990 PCT Pub. No. WO91/04264 PCT Pub. Date Apr. 4, 1991.A process for the production of 3-hydroxy-1,3,5(10)-estratrien-17-one by pyrolysi...
|
|
JP2916267B2 |
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ve...
|
|
JP2911553B2 |
Compounds of the general formula I have been described in which X, R<1>, R<2>, R<3> and R<4> have the meaning stated in the description, as well as processes for the preparation thereof, pharmaceutical products containing these compounds...
|
|
JP2898417B2 |
Products of general formula (I): …… in which R denotes H, …… … … R1 and R2 denote alkyl or form with the nitrogen atom a 5 or 6-membered heterocyclic ring optionally containing another hetero atom or R denotes alkyl, alkoxy,...
|
|
JP2894652B2 |
|
|
JP2893473B2 |
|
|
JPH11505531A |
PCT No. PCT/GB96/01118 Sec. 371 Date Apr. 10, 1998 Sec. 102(e) Date Apr. 10, 1998 PCT Filed May 9, 1996 PCT Pub. No. WO96/35415 PCT Pub. Date Nov. 14, 1996The invention relates to the use of a sesquiterpene for inhibiting an oxidative en...
|
|
JPH11124393A |
To prepare a pharmaceutical composition for preventing or reducing the loss of tissue vitality caused by adhesion of neutrophils to endothelial cells in a patient having a tissue injury by using dehydroepiandrosterone-3-sulfate or the li...
|
|
JPH11116595A |
To obtain a polymorphic progestagen compound having crystalline form suitable for utilization as a pharmaceutically active ingredient. This polymorphic progestagen-like steroidal compound, (17α)-17- hydroxy-11-methylene-19-norpregna-4,1...
|
|
JPH11106343A |
To provide a displacement type pump capable of being prevented from seizing by maintaining fine gaps around a rotor within a prescribed region even when being at a high temperature in an expanded state by setting different values on line...
|
